GlassScriptPhysician profile
Chris L Sturch
NPI 1619961943
$460.02
in general payments reported to CMS, 2019-2025
13 companies · $50.64 in 2025
The $50.64 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $38.75 · 2021: $60.46 · 2022: $30.51 · 2023: $74.15 · 2024: $90.94 · 2025: $50.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $215.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $116.98 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $94.45 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $59.62 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.79 | 2019-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $26.75 | 2020-2022 | |
| Allergan, INC. | $24.49 | 2019 | |
| Lilly USA, LLC | $18.23 | 2024 | Mounjaro |
| Abbott Laboratories | $17.90 | 2025 | Proclaim |
| Takeda Pharmaceuticals U.S.A., INC. | $16.74 | 2019 | |
| Amgen INC. | $15.34 | 2022 | |
| Genentech USA, INC. | $15.03 | 2019 | |
| Novo Nordisk INC | $11.89 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.81 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Sturch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.